Page 11 - reflections_dyslipidaemia_newsletter7_2024

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #7 2024

The authors review commonalities and differences across the
CLINICAL PEARLS FROM THE FACULTY clinical guidelines with respect to screening in patients with DM,
heart healthy lifestyle, ASCVD history, defining moderate, high,
Dyslipidaemia
and very high-risk, treatment recommendations for different age
groups and CV risk groups, and management of atherogenic
dyslipidaemia (high triglycerides and low HDL-C). While there
are some differences across the guidelines, with regards to
screening, assessing levels of risk, they all support LDL-C as
the primary target for screening and lipid management with
non-HDL-C, and more recently Apo B, as coprimary targets in
individuals with diabetes.
WATCH
PROF. SHAWKY DISCUSS THE
RELEVANCE OF THIS ARTICLE FOR CLICK HERE
CLINICAL PRACTICE. FOR THE LINK TO FULL ARTICLE

ARTICLES OF INTEREST

EPIDEMIOLOGY

1. Concordance of a High Lipoprotein(a) Concentration Among Relatives. Reeskamp LF, et al. JAMA Cardiol. 2023 Dec
1;8(12):1111-1118.

2. Non-High-Density Lipoprotein Cholesterol Levels From Childhood to Adulthood and Cardiovascular Disease
Events. Wu F, et al. JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.4819. Online ahead of print.

3. Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020. Ostrominski JW, et al.
JAMA Cardiol. 2023 Nov 1;8(11):1050-1060.
4. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years. Mendieta G, et al. J Am
Coll Cardiol. 2023 Nov 28;82(22):2069-2083.

GENETIC ANALYSIS

5. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis. Björnson E, et
al. J Am Coll Cardiol. 2024 Jan 23;83(3):385-395.
6. Impact of conducting a genetic study on the management of familial hypercholesterolemia. Marco-Benedí V, et al. J
Clin Lipidol. 2023 Nov-Dec;17(6):717-731.

RISK ASSESSMENT

7. Microplastics and Nanoplastics in Atheromas and Cardiovascular Events. Marfella R, et al. N Engl J Med. 2024 Mar
7;390(10):900-910.
8. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.
Small AM, et al. JAMA Cardiol. 2024 Apr 1;9(4):385-391. https://pubmed.ncbi.nlm.nih.gov/38353970

9. Impact of optimal cholesterol levels on subclinical atherosclerosis in the absence of risk factors in young adults.
Masrouri S, et al. Atherosclerosis. 2024 Mar 17:117520. https://pubmed.ncbi.nlm.nih.gov/38616451

TABLE OF CONTENTS